Short term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment

1992 ◽  
Vol 13 (2) ◽  
pp. 107-112 ◽  
Author(s):  
V. Scaioli ◽  
C. Milanese ◽  
A. Salmaggi ◽  
L. LaMantia ◽  
A. Campi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Steroid Treatment ◽  
Neurophysiological Monitoring ◽  
Short Term

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

2014 ◽  
Vol 3 (3) ◽  
pp. 294-302 ◽  
Author(s):  
Anthony T. Reder ◽  
Joel F. Oger ◽  
Ludwig Kappos ◽  
Paul O’Connor ◽  
Mark Rametta
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Β ◽  
Short Term

Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study

2006 ◽  
Vol 12 (5) ◽  
pp. 662-665 ◽  
Author(s):  
A Charil ◽  
D Caputo ◽  
R Cavarretta ◽  
M P Sormani ◽  
P Ferrante ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapse Rate ◽  
Magnetization Transfer ◽  
Small Sample ◽  
Cervical Cord ◽  
Magnetization Transfer Ratio ◽  
Short Term ◽  
Disease Evolution ◽  
Transfer Ratio ◽  
Relapsing Remitting

Background Magnetization transfer ratio (MTR) permits the quantitative estimation of cervical cord tissue damage in patients with multiple sclerosis (MS). Objective To determine whether a single time-point MTR scan of the cervical cord is associated with short-term disease evolution in patients with relapsing-remitting (RR) MS. Methods Using a 1.5-T magnetic resonance imaging (MRI) system with a tailored cervical cord phased array coil, fast short-tau inversion recovery (fast-STIR) and MTR scans were obtained from 14 untreated patients with RRMS at baseline. Cervical cord MTR histograms were derived. Over the 18- month follow-up period, relapse rate was measured and disability assessed by the Expanded Disability Status Scale (EDSS) score. Results Average cervical cord MTR was correlated with relapse rate ( r= -0.56, P = 0.037). A moderate correlation ( r values ranging from -0.33 to -0.36) between baseline cervical cord MTR metrics and EDSS changes over 18 months was also noted, albeit statistical significance was not reached ( P = 0.26 and 0.21, respectively) perhaps because of the relatively small sample size. Conclusions This study suggests that a ‘snapshot’ MT MRI assessment of the cervical cord may detect cervical cord tissue changes associated with short-term disease evolution in RRMS.

HYPERBARIC OXYGEN AND MULTIPLE SCLEROSIS: SHORT-TERM RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL

The Lancet ◽  
1985 ◽  
Vol 325 (8424) ◽  
pp. 297-300 ◽  
Author(s):  
MichaelP. Barnes ◽  
NiallE.F. Cartlidge ◽  
David Bates ◽  
JoyceM. French ◽  
DavidA. Shaw
Keyword(s):  
Multiple Sclerosis ◽  
Hyperbaric Oxygen ◽  
Double Blind Trial ◽  
Short Term ◽  
Double Blind ◽  
Blind Trial

scholarly journals Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

Neurology ◽  
2018 ◽  
Vol 91 (19) ◽  
pp. e1778-e1787 ◽  
Author(s):  
Kristen M. Krysko ◽  
Jennifer Graves ◽  
Mary Rensel ◽  
Bianca Weinstock-Guttman ◽  
Gregory Aaen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effect ◽  
Pediatric Patients ◽  
Dimethyl Fumarate ◽  
Short Term ◽  
Pediatric Multiple Sclerosis ◽  
Disease Modifying Therapies ◽  
The Us ◽  
Disease Modifying

ObjectiveTo characterize the use and safety of newer disease-modifying therapies (DMTs) in children with multiple sclerosis (MS) and clinically isolated syndrome (CIS) treated under 18 years of age.MethodsThis is a cohort study including children with MS or CIS followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. Newer DMTs were defined as agents receiving Food and Drug Administration approval or with increased use in adult MS after 2005.ResultsAs of July 2017, 1,019 pediatric patients with MS (n = 748) or CIS (n = 271) were enrolled (65% female, mean onset 13.0 ± 3.9 years, mean follow-up 3.5 ± 3.1 years, median 1.6 visits per year). Of these, 78% (n = 587) with MS and 11% (n = 31) with CIS received DMT before 18 years of age. This consisted of at least one newer DMT in 42%, including dimethyl fumarate (n = 102), natalizumab (n = 101), rituximab (n = 57), fingolimod (n = 37), daclizumab (n = 5), and teriflunomide (n = 3). Among 17%, the initial DMT prescribed was a newer agent (36 dimethyl fumarate, 30 natalizumab, 22 rituximab, 14 fingolimod, 2 teriflunomide). Over the last 10 years, the use of newer agents has increased, particularly in those ≥12 years and to lesser extent in those <12 years. The short-term side effect profiles of newer DMTs did not differ from those reported in adults.ConclusionNewer DMTs are often used in pediatric MS, and have similar short-term safety, tolerability, and side effect profiles as in adults. These findings may help inform pediatric MS management.

Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling

2007 ◽  
Vol 188 (1-2) ◽  
pp. 103-116 ◽  
Author(s):  
Aaron B. Kantor ◽  
Jun Deng ◽  
Emmanuelle Waubant ◽  
Hua Lin ◽  
Christopher H. Becker ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Short Term ◽  
Pharmacodynamic Effects

scholarly journals Efficacy of cognitive-behavioural psychotherapy in the treatment of chronic fatigue in patients with multiple sclerosis – a literature review

2021 ◽  
Vol 21 (1) ◽  
pp. 36-40
Author(s):  
Justyna Wiśniowska ◽  
◽  
Kamilla Puławska ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Chronic Fatigue ◽  
Research Groups ◽  
Long Term Effects ◽  
Short Term ◽  
Behavioural Model ◽  
Cognitive Behavioural ◽  
The Central Nervous System ◽  
Specific Factors

Fatigue is one of the most common symptoms seen in patients with multiple sclerosis. Cognitive-behavioural psychotherapy can be a non-pharmacological approach for these patients. Van Kessel and Moss-Morris developed a cognitive-behavioural model to explain multiple sclerosis-related fatigue (2006). According to this model, inflammatory and demyelinating factors present in the central nervous system trigger fatigue, while cognitive interpretation, anxiety, or depressive symptoms and resting lifestyle are maintaining factors. Based on the cognitive-behavioural model of fatigue in multiple sclerosis, a protocol encompassing 8 treatment sessions was developed. For over 10 years, studies have been conducted to verify the effectiveness of cognitive-behavioural psychotherapy in the treatment of fatigue in patients with multiple sclerosis. The so far obtained results show that cognitive-behavioural psychotherapy has a moderate short-term effect on reducing fatigue, while the effect size in the long-term is small. The obtained results were undoubtedly influenced by several factors: the heterogeneity of the procedures used, the size of the research groups, and the large number of disease-related intermediary variables. Further research should be conducted to identify specific factors responsible for the effectiveness of cognitive-behavioural psychotherapy in the treatment of fatigue and to assess the long-term effects of therapy.

Sign in / Sign up

Export Citation Format

Share Document